CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia treated with idarubicin and cytosine arabinoside

被引:8
|
作者
Handa, H
Motohashi, S
Isozumi, K
Komatsumoto, S
Nara, M
机构
[1] Gunma Univ, Sch Med, Dept Internal Med 3, Maebashi, Gumma 37185, Japan
[2] Ashikaga Red Cross Hosp, Dept Internal Med, Ashikaga, Tochigi, Japan
关键词
acute leukemia; myeloid/natural killer cell precursor; CD7; CD56; cytosine arabinoside; idarubicin;
D O I
10.1159/000063065
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We describe a 69-year-old Japanese male with acute leukemia with a CD7+ and CD56+ immunophenotype presenting with multiple lymphadenopathy. He was treated with idarubicin and cytosine arabinoside. Although the leukemia showed partial response, the patient did not achieve complete remission. He died of sepsis due to severe neutropenia after the third course of chemotherapy. His autopsy revealed blast infiltration in the lymph nodes, liver, spleen and vertebral bone marrow. Recently, CD7+ and CD56+ myeloid/natural killer precursor acute leukemia has been associated with a poor prognosis. Our case illustrates that myeloid/natural killer cell precursor acute leukemia shows some response to intensive chemotherapy for acute myeloid leukemia, but such therapy is insufficient to effect a cure. To overcome the resistance of this disease to chemotherapy, further studies should explore other treatment strategies. Copyright (C) 2002 S. Karger AG, Basel.
引用
收藏
页码:47 / 52
页数:6
相关论文
共 50 条
  • [21] HLA-DR-, CD33+, CD56+, CD16- MYELOID/NATURAL KILLER-CELL ACUTE-LEUKEMIA - A PREVIOUSLY UNRECOGNIZED FORM OF ACUTE-LEUKEMIA POTENTIALLY MISDIAGNOSED AS FRENCH-AMERICAN-BRITISH ACUTE MYELOID LEUKEMIA-M3
    SCOTT, AA
    HEAD, DR
    KOPECKY, KJ
    APPELBAUM, FR
    THEIL, KS
    GREVER, MR
    CHEN, IM
    WHITTAKER, MH
    GRIFFITH, BB
    LICHT, JD
    WAXMAN, S
    WHALEN, MM
    BANKHURST, AD
    RICHTER, LC
    GROGAN, TM
    WILLMAN, CL
    BLOOD, 1994, 84 (01) : 244 - 255
  • [22] Blastic CD56+ natural killer-cell lymphoma with primary cutaneous manifestation
    Berger, TG
    Voll, RE
    Simon, M
    Kiesewetter, F
    ACTA DERMATO-VENEREOLOGICA, 2004, 84 (01) : 53 - 56
  • [23] An unusual case of CD4+CD7+CD56+acute leukemia with overlapping features of type 2 dendritic cell (DC2) and myeloid/NK cell precursor acute leukemia
    Anargyrou, K
    Paterakis, G
    Boutsis, D
    Politou, M
    Papadhimitriou, SI
    Siakandaris, M
    Vassiliadis, J
    Androulakis, A
    Meletis, J
    Rombos, J
    Tassiopoulou, A
    Vaiopoulos, G
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2003, 71 (04) : 294 - 298
  • [24] Cytosine arabinoside, idarubicin and divided dose etoposide for the treatment of acute myeloid leukemia in elderly patients
    Hartmann, F
    Jacobs, G
    Gotto, H
    Schwamborn, J
    Pfreundschuh, M
    LEUKEMIA & LYMPHOMA, 2001, 42 (03) : 347 - 355
  • [25] Therapy-related CD7+ acute myeloid leukemia with trisomy 8 following acute monocytic leukemia
    Tanaka, M
    Kanamori, H
    Yamaji, S
    Fujimaki, K
    Tomita, N
    Fujisawa, S
    Ishigatsubo, Y
    ANTI-CANCER DRUGS, 2001, 12 (08) : 681 - 682
  • [26] CD5- CD56+ ''TCR silent peripheral T cell lymphomas'' are natural killer cell lymphomas.
    Emile, JF
    Boulland, ML
    Haioun, C
    Kanavaros, P
    Petrella, T
    DelfauLarue, MH
    Bensussan, A
    Farcet, JP
    Gaulard, P
    BLOOD, 1995, 86 (10) : 1296 - 1296
  • [27] Danurubicin, cytosine arabinoside, etoposide, dexamethasone (DCTER) versus idarubicin, cytosine arabinoside, thioguanine (IAT) in the treatment of childhood acute myeloid leukemia (AML).
    Rifai, S
    Mustafa, MM
    El Solh, H
    Al-Nasser, A
    Al-Mahr, M
    Mahgoub, N
    Belgaumi, A
    Ayas, M
    Al-Jefri, A
    Al-Musa, A
    Osman, M
    Al-Bagshi, M
    Al-Omari, A
    Baothman, A
    Al-Harbi, G
    Tarawah, A
    Al-Mulla, N
    Al-Asaad, T
    BLOOD, 1999, 94 (10) : 386B - 386B
  • [28] THE COST-EFFECTIVENESS OF IDARUBICIN CYTOSINE-ARABINOSIDE VERSUS DAUNORUBICIN CYTOSINE-ARABINOSIDE IN THE TREATMENT OF ADULTS WITH ACUTE MYELOID-LEUKEMIA
    PASHKO, S
    JACOBS, J
    SANTORSA, J
    CLINICAL THERAPEUTICS, 1991, 13 (03) : 353 - 360
  • [29] Myeloid/natural killer (NK) cell precursor acute leukemia as a distinct leukemia type
    Nishimura, Akira
    Yokoyama, Kazuaki
    Naruto, Takuya
    Yamagishi, Chika
    Imamura, Toshihiko
    Nakazono, Hiroto
    Kimura, Shunsuke
    Ito, Mieko
    Sagisaka, Maiko
    Tanaka, Yukie
    Piao, Jinhua
    Namikawa, Yui
    Yanagimachi, Masakatsu
    Isoda, Takeshi
    Kanai, Akinori
    Matsui, Hirotaka
    Isobe, Tomoya
    Sato-Otsubo, Aiko
    Higuchi, Naoko
    Takada, Akiko
    Okuno, Haruna
    Saito, Shoji
    Karakawa, Shuhei
    Kobayashi, Shogo
    Hasegawa, Daisuke
    Fujisaki, Hiroyuki
    Hasegawa, Daiichiro
    Koike, Kazutoshi
    Koike, Takashi
    Rai, Shinya
    Umeda, Katsutsugu
    Sano, Hideki
    Sekinaka, Yujin
    Ogawa, Atsushi
    Kinoshita, Akitoshi
    Shiba, Norio
    Miki, Mizuka
    Kimura, Fumihiko
    Nakayama, Hideki
    Nakazawa, Yozo
    Taga, Takashi
    Taki, Tomohiko
    Adachi, Souichi
    Manabe, Atsushi
    Koh, Katsuyoshi
    Ishida, Yasushi
    Takita, Junko
    Ishikawa, Fumihiko
    Goto, Hiroaki
    Morio, Tomohiro
    SCIENCE ADVANCES, 2023, 9 (50)
  • [30] CD56+ TdT+ blastic natural killer cell tumor of the skin -: A primitive systemic malignancy related to myelomonocytic leukemia
    Khoury, JD
    Medeiros, LJ
    Manning, JT
    Sulak, LE
    Bueso-Ramos, C
    Jones, D
    CANCER, 2002, 94 (09) : 2401 - 2408